Mechanisms of Action of Ready-to-Use Therapies in Hematologic Malignancies: From Clinical Impact to Future Directions

Off-the-shelf cellular therapies, utilizing allogeneic T cells derived from healthy donors, represent a promising alternative to autologous chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies such as leukemias and lymphomas. Unlike autologous approaches, which require the patient’s own cell collection, modification, and expansion, off-the-shelf therapies can be prepared in advance, substantially reducing treatment timelines, decreasing costs, and improving global accessibility. Recent technological advancements, including gene-editing techniques such as CRISPR-Cas9, HLA-matching strategies, and next-generation CAR-T cell designs, have been pivotal in overcoming limitations such as immune rejection and graft-versus-host disease. Alternative cellular sources such as umbilical cord blood and induced pluripotent stem cells are also being explored to enhance scalability and compatibility. However, ethical concerns related to donor cell sourcing and the use of gene-editing technologies must be addressed to ensure responsible clinical implementation. This review outlines the mechanisms, recent advances, challenges, ethical issues, and prospects of off-the-shelf cellular therapies, emphasizing their transformative potential in cancer immunotherapy.